Results 11 to 20 of about 5,124 (246)

Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet-α, protamine). [PDF]

Br J Clin Pharmacol
Bleeding events are common in patients prescribed anticoagulants and can have devastating consequences. Several specific and nonspecific agents have been developed to reverse the effects of anticoagulant drugs or toxins. Vitamin K, as the oldest of these
Bekka E, Liakoni E.
europepmc   +3 more sources

Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials

Medicina, 2023
Background and Objectives: The effectiveness and safety of idarucizumab for the reversal of the effects of dabigatran have been proven. However, there remains a paucity of literature comprehensively investigating outcomes in real-world patients.
Jhih-Wei Dai, Chien-Ho Wang, Chan-Lin Chu, Shu-Chen Liao   +3 more
doaj   +2 more sources

Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study

Frontiers in Neurology, 2023
BackgroundIntracranial hemorrhage (ICH) is a rare but serious side effect associated with the use of oral anticoagulants, such as dabigatran. The specific reversal agent for dabigatran, idarucizumab, is available for the management of individuals with ...
Nils Kuklik, Nils Kuklik, Anika Hüsing, Andreas Stang, Andreas Stang, Marcus Brinkmann, Marcus Brinkmann, Christoph C. Eschenfelder, Christian Weimar, Christian Weimar, Hans-Christoph Diener   +10 more
doaj   +2 more sources

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds

Clinical and Applied Thrombosis/Hemostasis, 2022
Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors.
Alex C. Spyropoulos MD, Bríain Ó Hartaigh PhD, Zhun Cao PhD, MA, Harjeet Caberwal PharmD, Craig Lipkin MS, Michaela Petrini PA-C, MHS, Cheng Wang MD, PhD   +6 more
doaj   +2 more sources

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals [PDF]

Research and Practice in Thrombosis and Haemostasis, 2021
Background Idarucizumab, a monoclonal antibody fragment that reverses the anticoagulant effect of dabigatran, was approved for use in Canada in 2016. Objective Our objective was to assess the safety of idarucizumab among patients who received the drug ...
Jameel Abdulrehman, Sahar Zarabi, Carolyne Elbaz, Kerstin deWit, Yulia Lin, Michelle Sholzberg, Rita Selby   +6 more
doaj   +2 more sources

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting

Frontiers in Medicine, 2020
Background: Idarucizumab has been included in guidelines for the management of bleeding or surgical procedure in dabigatran-treated patients without need for biological monitoring.
Nicolas Gendron, Nicolas Gendron, Richard Chocron, Richard Chocron, Paul Billoir, Julien Brunier, Laurence Camoin-Jau, Marie Tuffigo, Dorothée Faille, Dorothée Faille, Dorian Teissandier, Juliette Gay, Juliette Gay, Emmanuelle de Raucourt, Emmanuelle de Raucourt, Ludovic Suner, Corentin Bonnet, Anne-Céline Martin, Anne-Céline Martin, Dominique Lasne, Chayma Ladhari, Aurélien Lebreton, Laurent Bertoletti, Laurent Bertoletti, Nadine Ajzenberg, Nadine Ajzenberg, Pascale Gaussem, Pascale Gaussem, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Véronique Le Cam Duchez, Alain Viallon, Pierre-Marie Roy, Pierre-Marie Roy, Agnès Lillo-le Louët, Agnès Lillo-le Louët, David M. Smadja, David M. Smadja, David M. Smadja   +39 more
doaj   +2 more sources

Idarucizumab for Dabigatran Reversal

New England Journal of Medicine, 2015
Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of ...
Pollack Jr, C.V., Reilly, P.A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R.A., Dubiel, R., Huisman, M.V., Hylek, E.M., Kamphuisen, P.W., Kreuzer, J., Levy, J.H., Sellke, F.W., Stangier, J., Steiner, T., Wang, B., Kam, C.W., Weitz, J.I.   +17 more
openaire   +4 more sources

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran

Drug Design, Development and Therapy, 2016
Pierre Sié Hematology Laboratory, Academic Hospital of Toulouse, Hospital Rangueil, Toulouse, France Abstract: Idarucizumab is the first targeted antidote of dabigatran, a direct oral anticoagulant used for prevention and treatment of venous ...
Sié P
doaj   +3 more sources

Perioperative Myocardial Infarction Following Dabigatran Reversal With Idarucizumab in a Patient Undergoing Orthotopic Liver Transplantation. [PDF]

Cureus, 2023
Insufficient information is available regarding the administration of anticoagulants, specifically direct oral anticoagulants, in individuals with cirrhosis awaiting liver transplantation.
Barroso A, Martinez-Gonzalez MC, Knowlson N, Miguel AM, Perez G.   +4 more
europepmc   +2 more sources

Barriers in Access to Idarucizumab in Ischemic Stroke in a Middle-Income Country. [PDF]

Neurohospitalist, 2023
Background and Purpose Current stroke guidelines contraindicate the use of thrombolytics if oral anticoagulants are taken within 48 hours of symptom onset.
Rivillas J, Llanos-Leyton N, Moreno-Vargas E, Bayona H, Jaramillo E, Kafury D, Amaya P.   +6 more
europepmc   +2 more sources